SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-006042
Filing Date
2022-04-27
Accepted
2022-04-27 07:45:38
Documents
14
Period of Report
2022-04-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ettx-20220427x8k.htm   iXBRL 8-K 37057
2 EX-99.1 ettx-20220427xex99d1.htm EX-99.1 78189
  Complete submission text file 0001558370-22-006042.txt   252672

Data Files

Seq Description Document Type Size
3 EX-101.SCH ettx-20220427.xsd EX-101.SCH 4001
4 EX-101.DEF ettx-20220427_def.xml EX-101.DEF 3177
5 EX-101.LAB ettx-20220427_lab.xml EX-101.LAB 15896
6 EX-101.PRE ettx-20220427_pre.xml EX-101.PRE 10810
8 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20220427x8k_htm.xml XML 4865
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38670 | Film No.: 22856391
SIC: 2834 Pharmaceutical Preparations